BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 38061885)

  • 1. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
    Seol HY; Kim YS; Kim SJ
    Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
    Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
    Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
    Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
    Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
    EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
    Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
    Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between
    Zhao L; Liu J; Wang H; Shi J
    Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning based on clinico-biological features integrated
    Ren C; Zhang J; Qi M; Zhang J; Zhang Y; Song S; Sun Y; Cheng J
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1538-1549. PubMed ID: 33057772
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
    Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
    Wang D; Li Y; Chen X; Li P
    Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Liu F; Xiang Z; Li Q; Fang X; Zhou J; Yang X; Lin H; Yang Q
    Clin Radiol; 2024 Jan; 79(1):e147-e155. PubMed ID: 37884401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using
    Wang Y; Lyu D; Cheng C; Zhou T; Tu W; Xiao Y; Zuo C; Fan L; Liu S
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):185. PubMed ID: 38598007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The correlation between PD-L1 expression and metabolic parameters of
    Xu X; Li J; Yang Y; Sang S; Deng S
    Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of a prognostic nomogram combining PET/CT metabolic parameters and blood inflammatory markers for non-small cell lung cancer treated with first-line chemotherapy].
    Kong D; Song L; Xiang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Dec; 43(12):2139-2144. PubMed ID: 38189402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value on SUV-derived parameters assessed on
    Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
    BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor metabolic volume by
    Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Shiono A; Miura Y; Murayama Y; Kobayashi K; Kagamu H; Kuji I
    Sci Rep; 2020 Sep; 10(1):14990. PubMed ID: 32929123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.